Tesamorelin 10mg for Sale | 99% Pure Stabilized GHRH Analog (Visceral Fat Research)

Of all the growth-hormone-releasing peptides researchers work with, exactly one has walked the entire FDA gauntlet — clinical trials, safety review, approval — and come out the other side as a genuine prescription medicine. That peptide is Tesamorelin. Marketed as Egrifta, it’s the only GHRH analog to earn FDA approval, specifically for reducing the deep, dangerous visceral fat that accumulates in HIV-associated lipodystrophy. In its pivotal Phase 3 program of over 800 patients, it cut visceral adipose tissue by roughly 15–18% in 26 weeks — a regulator-grade evidence base almost no other research peptide can claim.

Tesamorelin 10mg is the high-concentration, research-grade form of that stabilized 44-amino-acid peptide — verified 99%+ pure, lyophilized, and sized for large-scale, longitudinal work. What makes it distinctive isn’t just the approval; it’s the specificity — a preferential effect on deep abdominal fat that sets it apart from every other secretagogue. Let’s go deep on the structure, the mechanism, the visceral-fat biology, and where to buy it.

Scope note: research-grade material for in-vitro and laboratory research by qualified professionals only. This is not the approved pharmaceutical (Egrifta), is approved only for HIV-associated lipodystrophy (not weight loss or anti-aging), is not for human or veterinary use, and nothing here is a dosing protocol.

What Sets Tesamorelin Apart: The Full GHRH Sequence, Stabilized

Most GHRH-based research peptides are fragments. Sermorelin is GHRH(1-29) — just the first 29 residues. Tesamorelin is different: it’s the complete 44-amino-acid sequence of endogenous GHRH, carrying the full native structure.

But a raw 44-residue GHRH would degrade almost instantly in circulation. So the molecule (developmental code TH9507, supplied as the acetate salt) was engineered with one elegant modification: a trans-3-hexenoyl group attached at the N-terminus (Regeneris, 2026). That small lipid addition shields the peptide from rapid enzymatic breakdown while leaving its receptor activity fully intact. Full native sequence, dramatically better stability — that’s the whole design, and it’s why the copy calls out the “exact attachment of the hexenoyl moiety” as essential. Get that modification right and you have a stable, potent GHRH analog; get it wrong and you have a peptide that falls apart before it can act.

The Only FDA-Approved GHRH Analog

This is Tesamorelin‘s headline distinction, and it’s worth understanding precisely. It was FDA-approved in November 2010 as Egrifta (Theratechnologies), reformulated as Egrifta SV in 2019, and updated again as the more concentrated Egrifta WR in March 2025. The approved indication is narrow — reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy, a condition where antiretroviral therapy drives dangerous fat accumulation around the internal organs.

Why does that matter to a researcher? Because it means Tesamorelin‘s pharmacology, safety profile, and efficacy rest on regulator-grade human evidence — two pivotal Phase 3 trials, 52- and 104-week extension data — rather than the thinner preclinical record behind most research peptides. That’s a genuine E-E-A-T advantage when you’re designing a study around GHRH signaling. Two honest caveats, though: the approval covers the HIV-lipodystrophy indication only (not general weight management or anti-aging), and the approved product is Egrifta — this research-grade powder is the same molecule but not the finished, regulated drug, and isn’t for human use.

How Tesamorelin Works: Amplifying Your Own Growth Hormone

Here’s the mechanistic core, and it’s what makes Tesamorelin more physiologically interesting than simply injecting growth hormone. It binds the GHRH receptor on the somatotroph cells of the anterior pituitary, activating a Gs-coupled adenylate cyclase cascade that raises cAMP and prompts the pituitary to release the body’s own stored growth hormone. That GH pulse then travels to the liver, driving production of IGF-1, which mediates the downstream lipolytic and anabolic effects.

The crucial word is pulsatile. Because Tesamorelin works through the pituitary rather than flooding the bloodstream with external GH, it preserves the natural rhythm of secretion — and, importantly, the natural brakes. Somatostatin and IGF-1 negative feedback stay intact, modulating the response the way the body normally would. Injected recombinant GH bypasses all of that regulation; Tesamorelin works with it. One more elegant detail: the peptide itself clears blood in roughly 8–11 minutes, but that’s fine — what matters is the downstream GH pulse and the longer-lasting IGF-1 rise it triggers, which is why the metabolic effect builds over months rather than minutes.

Why Visceral Fat Specifically?

One of the most-studied aspects of Tesamorelin is why it targets deep abdominal fat so preferentially — and the answer is real receptor biology. Visceral adipocytes (the fat cells packed around the internal organs) have a higher density of beta-adrenergic receptors and greater sensitivity to lipolytic hormones than subcutaneous fat (Peptidepedia, 2026). So when GH-driven lipolytic signaling rises, that visceral compartment responds first and hardest.

This is why Tesamorelin research centers on VAT (visceral adipose tissue) rather than fat generally — it’s not a blunt “fat-loss” tool, it’s a compound with a genuine tissue preference, which is exactly what made it valuable for lipodystrophy, where visceral fat is the specific problem. For metabolic researchers, that specificity is the whole appeal: a way to probe visceral-fat lipolysis distinct from subcutaneous fat.

Where Tesamorelin 10mg Fits in Research

Research Focus	What’s Being Investigated
Visceral Adipose Tissue	Lipolysis specifically within deep abdominal fat stores
Endocrine Signaling	GHRH-pituitary axis efficiency under sustained stimulation
Metabolic Homeostasis	Effects on lipid profiles and insulin sensitivity
GH Pulsatility	Physiologic pulsatile release vs exogenous GH
IGF-1 Axis	Downstream hepatic IGF-1 dynamics
Cognitive Research	IGF-1-linked executive function and memory in aging models

Research Scope & Honest Notes

A straight read, because you deserve one. Tesamorelin‘s evidence base is unusually strong for a research peptide — but it’s specific. It’s approved and validated for HIV-associated lipodystrophy, not for general body composition or anti-aging, and the large-scale trials didn’t test those uses. It’s also pregnancy Category X. And to be clear on identity: this is research-grade material, not the Egrifta product, and it’s supplied for laboratory investigation — the impressive clinical data tells you how the molecule behaves, not how a vial should be used. Strong science, clearly bounded — which is exactly how good research treats it.

Expanded Technical Specifications

Property	Specification
Compound Name	Tesamorelin (TH9507)
CAS Number	218949-48-5
Vial Concentration	10mg single compound
Sequence	Full GHRH(1-44) with N-terminal trans-3-hexenoyl group
Molecular Formula	C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular Weight	~5135.9 g/mol
Key Modification	trans-3-hexenoyl moiety (enzymatic-degradation resistance)
Salt Form	Acetate
Class	Stabilized GHRH analog (growth hormone secretagogue)
Receptor Target	GHRH receptor (anterior pituitary)
Purity Rating	>99% (HPLC & MS verified)
Format	White lyophilized powder
Storage	-20°C, protected from light and moisture

The GLP1 Peptides Quality Standard

Standard	What You Get
99%+ Purity	Every batch confirmed by HPLC and Mass Spectrometry
Superior Lyophilization	Freeze-drying that protects the peptide from degradation
Analytical Transparency	A batch-specific Certificate of Analysis (COA) with every order
Precision Synthesis	Verified attachment of the hexenoyl moiety — essential to stability

That hexenoyl modification is central to Tesamorelin‘s identity, so the COA is doing real work here — it confirms you have the genuine, correctly-modified 44-residue analog, not a bare or degraded GHRH sequence.

How to Reconstitute Tesamorelin 10mg — Step by Step

Tesamorelin is a large, delicate peptide, so gentle handling genuinely matters. Here’s the full walkthrough.

Step	What to Do
1	Let the sealed vial reach room temperature to prevent condensation
2	Wipe the stopper with an alcohol swab before piercing
3	Draw your chosen volume of bacteriostatic (or sterile) water into a sterile syringe
4	Add the water slowly down the inner glass wall — never directly onto the powder
5	Roll or swirl gently until dissolved — never shake (shaking denatures this peptide fast)
6	Let it rest until the solution is completely clear
7	Aliquot into single-use portions to avoid freeze-thaw

Concentration guide (10mg vial): add 1.25 mL for 8 mg/mL (the concentration the reformulated product uses), 2 mL for 5 mg/mL, or 5 mL for 2 mg/mL — more solvent means finer titration control.

How to Store Tesamorelin 10mg

Lyophilized powder: -20°C, sealed, dark, and dry — stable long-term.
Reconstituted solution: keep refrigerated at 2–8°C, protected from light, and use within a few weeks.
Never freeze the reconstituted solution, and never shake it — both damage the peptide.
Inspect: a proper solution is clear and colorless; discard anything cloudy or discolored.

Tesamorelin vs Sermorelin vs CJC-1295 vs Ipamorelin

Compound	Structure	Class	Distinction
Tesamorelin (this product)	Full GHRH(1-44) + hexenoyl	Stabilized GHRH analog	Only FDA-approved; visceral-fat specific
Sermorelin	GHRH(1-29)	GHRH analog	The original, short-acting fragment
CJC-1295	Modified GHRH(1-29) ± DAC	GHRH analog	Stabilized/long-acting via substitutions or acylation
Ipamorelin	Pentapeptide	GHS (ghrelin mimetic)	Different receptor; often paired with a GHRH analog

The clean framing: Tesamorelin is the full-length, FDA-validated, visceral-fat-focused member of the GHRH family — where Sermorelin and CJC-1295 are fragment-based analogs and Ipamorelin works through an entirely different (GHS) receptor. All prompt the pituitary to release the body’s own GH rather than supplying it directly, which is what separates the whole family from injected recombinant hGH.

Tesamorelin 10mg for Sale — Shipping Worldwide

Our research-grade Tesamorelin 10mg ships as HPLC/MS-verified, COA-backed lyophilized vials, sealed and bench-ready. We fulfill orders for laboratories and independent researchers across the highest-demand markets:

🇺🇸 USA — fast domestic dispatch
🇨🇦 Canada — reliable cross-border delivery
🇩🇪 Germany (Deutschland) — trusted EU logistics
🇫🇷 France — secure European shipping

When you buy Tesamorelin 10mg from GLP1 Peptides, you get the only FDA-approved GHRH analog in a high-yield, verified format — one lot, one COA, with the confirmed hexenoyl modification that defines the molecule. For visceral-fat and GHRH-axis research, that verified identity is the foundation everything else rests on.

FAQs about Tesamorelin 10mg

1. What is Tesamorelin 10mg? A high-concentration 10mg vial of Tesamorelin, a stabilized full-length (44-amino-acid) GHRH analog with an N-terminal hexenoyl modification, supplied as a lyophilized powder for visceral-fat and endocrine research.

2. What makes Tesamorelin unique among GHRH peptides? It’s the only GHRH analog to earn full FDA approval (as Egrifta), it uses the complete 44-residue GHRH sequence rather than a fragment, and it has a preferential effect on deep visceral fat

3. What is the hexenoyl group for? The trans-3-hexenoyl modification at the N-terminus protects the peptide from rapid enzymatic degradation while preserving its full receptor activity — it’s what makes the otherwise-fragile 44-residue sequence stable

4. How does Tesamorelin work? It binds the GHRH receptor on the pituitary, triggering cAMP signaling that releases the body’s own growth hormone in a natural pulsatile pattern, which raises IGF-1 and drives lipolysis — preferentially in visceral fat.

5. Why does Tesamorelin target visceral fat specifically? Visceral adipocytes have higher beta-adrenergic receptor density and greater lipolytic sensitivity than subcutaneous fat, so they respond first and hardest to GH-driven lipolysis

6. How is Tesamorelin different from injected growth hormone? Injected GH floods the system and bypasses regulation; Tesamorelin works through the pituitary, preserving natural pulsatility and the somatostatin/IGF-1 feedback loops — a more physiologic profile.

7. Is Tesamorelin FDA approved? The pharmaceutical (Egrifta) is FDA-approved, but only for HIV-associated lipodystrophy — not weight loss or anti-aging. This research-grade material is not the approved drug and is for laboratory use only.

8. How does Tesamorelin compare to Sermorelin and CJC-1295? All three are GHRH-pathway analogs, but Tesamorelin is the full 44-residue, FDA-approved, visceral-fat-specific one; Sermorelin is the short GHRH(1-29) fragment and CJC-1295 is a modified/longer-acting fragment.

9. How do I reconstitute Tesamorelin 10mg? Warm the vial, sanitize the stopper, add bacteriostatic or sterile water slowly down the glass wall, roll gently (never shake), then aliquot. Full steps and a concentration guide are above.

10. How should Tesamorelin be stored? Lyophilized powder at -20°C, sealed and dark; reconstituted solution refrigerated at 2–8°C, never frozen, never shaken, used within a few weeks.

11. Is Tesamorelin banned in sport? Yes — GHRH analogs fall under WADA’s S2 category and are prohibited in competitive sport.

12. Where can I buy Tesamorelin 10mg internationally? GLP1 Peptides ships research-grade, COA-verified Tesamorelin 10mg to the USA, Canada, Germany, and France in sealed lyophilized vials. See the shipping section above.